RxSight RXST
NASDAQ RXST
$4.90 +0.13 (+2.73%)
At close: Sep 30, 2026 · 4:00 PM EDT

RxSight (RXST) Current Deferred Revenue (2025 - 2026)

Updated

RxSight (RXST) recorded Current Deferred Revenue of $6.88 million in Q2 2026.

Analysis

RxSight (RXST) Current Deferred Revenue (2025 - 2026) Analysis & Trends

At the end of FY2025, RxSight reported Current Deferred Revenue of $3.26 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 251.30 Bn 230.45 Bn 4.88 Bn
2 Abbott Laboratories 174.70 Bn 145.78 Bn 7.27 Bn
3 Danaher 158.94 Bn 142.76 Bn 3.61 Bn
4 Intuitive Surgical 145.87 Bn 125.42 Bn 1.96 Bn
5 Medtronic 111.49 Bn 77.36 Bn 6.34 Bn
6 Stryker 106.96 Bn 93.08 Bn 4.50 Bn
7 Boston Scientific 63.62 Bn 58.63 Bn 3.85 Bn
8 Edwards Lifesciences 50.80 Bn 34.92 Bn 1.35 Bn
9 Becton Dickinson 49.59 Bn 46.74 Bn 2.32 Bn
10 RxSight 198.36 Mn -10.44 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6.88 Mn
Dec 31, 2025 3.26 Mn
API Access

RxSight Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=RXST&period=max&api_key=YOUR_API_KEY